Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial

Table 2 Improvement of motor function in the lower extremities and urinary function 12 weeks after treatment

	Time required to walk 10 m (sec)			Time required to walk downstairs (sec)			Detrusor overactivity		Detrusor-sphincter dyssnergia
Case no.	Before treatment	After treatment	% improvement	Before treatment	After treatment	% Improvement	Before treatment	After treatment	Before treatment	After treatment
1	26.5	21.6	18.5	N.E.			No	No	No	No
2	15.5	9.8	36.8	N.E.			Yes	No	No	No
3	11.5	10.5	8.7	8.6	7.7	10.5	Yes	No	Yes	Yes
4	N.E.			N.E.			Yes	No	Yes	Yes
5	5.3	4.9	7.5	3.8	3.7	2.6	No	No	Yes	No
6	5.9	6.2	-5.1	4.1	4.2	-2.4	No	No	Yes	No
7	8.9	9.5	-6.7	9.2	7.9	14.1	No	No	No	No
8	12.6	13.3	-5.6	9.5	8.6	9.5	Yes	No	Yes	Yes
9	N.E.			N.E.			Yes	No	No	No
10	20	25.1	-25.5	N.E.			No	No	No	No
11	29.5	32.5	-10.2	N.E.			Yes	No	Yes	Yes
12	6.6	6.9	-4.5	4.4	4.3	2.3	Yes	No	Yes	No
13	22.8	21.3	6.6	N.E.			Yes	No	No	No
14	15.4	11.3	26.6	14.3	11.4	20.3	No	No	No	No
15	N.E.	N.E.		N.E.			Yes	No	No	No
16	13.7	20.9	-52.6	N.E.			Yes	Yes	Yes	Yes
17	13.3	11.5	13.5	10.0	7.3	27	Yes	Yes	No	No
18	N.E.			N.E.			Yes	Yes	No	No
19	N.E.			N.E.			Yes	Yes	Yes	No
20	6.9	5.7	17.4	4.5	3.5	22.2	No	No	No	No
21	5.7	4.1	28.1	3.6	3.5	2.8	Yes	No	No	No
22	10.3	6.8	34	9.4	4.4	53.2	Yes	Yes	Yes	Yes
23	N.E.			N.E.			No	No	Yes	No
24	4.5	4.3	4.4	3.2	3.4	-6.3	Yes	No	No	No
Remarks								% improvement:		% improvement:
								68.8 (P = 0.0094)^a		45.5 (P = 0.0736)^a

^aStatistical significance was determined by the McNemar test. N.E.; not evaluated because of high OMDS.

ISSN: 1741-7015